Nevertheless, according to the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) findings from October 2023, there is no evidence to suggest a causal relationship between GLP-1 receptor agonists (including exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide) and thyroid cancer [56]. Here, GLP1R is linked to thyroid cancer.